S&P 500 highs, Beige Book drag
US equities stayed risk-on and the S&P 500 set intraday and closing all-time highs. Geopolitics didn’t knock it off course. Flows kept chasing momentum and big-cap growth, and volatility stayed too quiet to force anyone out of risk.
The other signal was the Fed’s Beige Book, and it wasn’t exactly celebratory. It flagged slowing activity in several regions, cooling hiring and spending, and a consumer showing greater price sensitivity and more financial strain (including rising food bank demand). That’s not the setup for a big cyclical grab. It does matter for positioning: indexes can grind higher on liquidity and earnings resilience, but this kind of late-cycle texture makes it harder to lean all-in on a clean “soft landing” narrative without better confirmation.
Geopolitics stayed in the background. Western finance ministers (including New Zealand) warned a prolonged Iran conflict could threaten global stability. Norway’s sovereign wealth fund said it’s maintaining high US asset exposure despite geopolitical and fiscal risks. Not a catalyst, but it reinforces the idea that there’s still a deep pool of structural demand behind dips.
A regulatory hit, an IPO window
The sharpest single-stock move was Live Nation (LYV) after a court found it monopolized ticketing; the penalty phase is still ahead. Shares sold off, and the problem wasn’t concerts. It was remedy risk—what gets forced to change, what gets constrained, and how bargaining power shifts to venues and artists before anyone even knows the final numbers. This is the kind of overhang that lingers because the timeline just got longer.
On the brighter side, capital markets looked open. Madison Air Solutions (MDBN) got its IPO done, raising $2.23 billion, billed as the largest US industrial IPO in nearly 27 years. Large, real-economy issuance clearing at size is a useful tell: when indexes are at highs and the vol regime is calm, institutions will take fresh supply and issuers will finally test demand.
Smaller but same direction: Goldstorm Metalsupsized a private placement to $7 million.
Healthcare growth, credit relief
Healthcare brought two versions of expansion.
- Hims & Hers (HIMS) moved higher as it moved closer to entering peptide sales after a US regulatory plan advanced. The market treated it as adjacency value: a wider TAM and more “platform” framing, less single-product story.
- Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million to add to its oncology portfolio. Not a needle-mover, but it’s the standard large-pharma playbook—buy targeted shots on goal rather than wait on internal timelines.
In alternatives, Blue Owl (OWL) jumped, posting its largest two-day gain since November 2022, as private credit jitters eased. The point wasn’t that cycle risk vanished. It was that the market backed away from a near-term stress narrative and was willing again to own yield platforms and fee streams. When fear comes out of credit-adjacent names, the snapback is quick because positioning tends to get crowded on the short side.
Two other headlines were more incremental:
- Raytheon won a $234.8 million AMRAAM ER production contract (backlog visibility).
- Ford’s top EV executive left amid a reorg merging EV and other units (integration push, execution uncertainty).
What mattered
- S&P 500 at new highs while the Beige Book leaned softer: strong tape, late-cycle undertone.
- LYV took the regulatory punch; the overhang is remedies and timeline, not demand.
- MDBN’s $2.23B IPO clearing suggests the issuance window is open.
- HIMS / LLY / OWL: growth still gets paid when stress narratives cool.
The market can float on momentum for a while, but the macro details are starting to argue for selectivity.